Related Experiment Video
Updated: Jul 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
VEXAS syndrome presenting with severe cutaneous manifestations, inflammatory arthritis, and myelodysplastic syndrome
Jared Tesch1, Nada Alrifai2, Beth Honl3
1Department of Biological Sciences, North Dakota State University, 1340 Bolley Drive, Fargo, ND 58102, United States.
Abstract:
VEXAS syndrome is a recently identified adult-onset autoinflammatory disorder caused by somatic mutations in the UBA1 gene, leading to systematic inflammation and hematological dysfunctions. We present the case of a 71-year-old man with a prolonged history of cutaneous lesions and inflammatory arthritis that is refractory. Despite the treatment with multiple immunosuppressive therapies, his symptoms persisted alongside macrocytic anemia and thrombocytopenia. Genetic testing confirmed a UBA1 mutation, which established the diagnosis of VEXAS syndrome. A subsequent bone marrow biopsy revealed myelodysplastic syndrome. This case highlights the importance of early recognition of VEXAS syndrome, particularly in patients with multisystemic involvement and treatment-refractory disease. Therapies such as JAK inhibitors may provide effective disease control in patients who are not candidates for hematopoietic stem cell transplantation.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease IV: Clinical Manifestations
Nephrotic Syndrome II : Assessment and Medical Management
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...